Is Buying Coherus Biosciences Inc (NASDAQ:CHRS), Having Lower Short Interest a Winning Strategy?

June 27, 2018 - By Dolores Ford

Coherus BioSciences, Inc. (NASDAQ:CHRS) Logo

Investors sentiment increased to 1.49 in 2018 Q1. Its up 0.33, from 1.16 in 2017Q4. It increased, as 10 investors sold Coherus BioSciences, Inc. shares while 27 reduced holdings. 21 funds opened positions while 34 raised stakes. 51.20 million shares or 4.31% more from 49.09 million shares in 2017Q4 were reported.
Tiaa Cref Inv Management Limited Co reported 0.01% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Macquarie Grp reported 0.01% stake. Ameritas Invest Partners reported 3,367 shares. Gp One Trading L P invested 0% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS). Omers Administration accumulated 23,400 shares. Tekla Cap Mngmt Ltd holds 0.08% or 181,023 shares in its portfolio. Balyasny Asset Mgmt Limited Co accumulated 14,751 shares. First Personal Svcs holds 876 shares. Laurion Cap Limited Partnership has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Jacobs Levy Equity holds 0.01% or 33,506 shares. Daiwa Secs Group has 320 shares. Trexquant Invest L P stated it has 35,252 shares. Quantbot Techs Limited Partnership holds 2,209 shares. Sphera Funds invested in 0.45% or 270,000 shares. Bnp Paribas Arbitrage invested in 8,655 shares.

The stock of Coherus Biosciences Inc (NASDAQ:CHRS) registered a decrease of 7.31% in short interest. CHRS’s total short interest was 6.04 million shares in June as published by FINRA. Its down 7.31% from 6.52 million shares, reported previously. With 370,200 shares average volume, it will take short sellers 16 days to cover their CHRS’s short positions. The short interest to Coherus Biosciences Inc’s float is 14.51%.

The stock decreased 0.66% or $0.1 during the last trading session, reaching $15. About 5,516 shares traded. Coherus BioSciences, Inc. (NASDAQ:CHRS) has declined 24.26% since June 27, 2017 and is downtrending. It has underperformed by 36.83% the S&P500.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $991.54 million. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

Among 2 analysts covering Coherus Biosciences (NASDAQ:CHRS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Coherus Biosciences has $25 highest and $15.0 lowest target. $23.50’s average target is 56.67% above currents $15 stock price. Coherus Biosciences had 3 analyst reports since March 9, 2018 according to SRatingsIntel. The stock of Coherus BioSciences, Inc. (NASDAQ:CHRS) earned “Buy” rating by Maxim Group on Friday, March 9. Citigroup maintained it with “Buy” rating and $25 target in Friday, March 9 report. The stock of Coherus BioSciences, Inc. (NASDAQ:CHRS) earned “Buy” rating by Maxim Group on Monday, May 14.

More important recent Coherus BioSciences, Inc. (NASDAQ:CHRS) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” on June 21, 2018, also Benzinga.com published article titled: “44 Biggest Movers From Yesterday”, Benzinga.com published: “36 Stocks Moving In Monday’s Mid-Day Session” on June 25, 2018. More interesting news about Coherus BioSciences, Inc. (NASDAQ:CHRS) was released by: Globenewswire.com and their article: “Coherus BioSciences Announces New Employment Inducement Grants” with publication date: June 22, 2018.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.